NICE Appraisal Strikes Down Three Ovarian Cancer Drugs In The U.K.
This article was originally published in The Pink Sheet Daily
Executive Summary
As the result of a multiple technology appraisal from Britain’s U.K.’s reimbursement watchdog, NICE, three ovarian cancer drugs will disappear from the publicly funded NHS.